Jaguar Health Reports Modest Revenue Increase in Q3 2025 Financials

San Francisco, CA - Jaguar Health, Inc. has announced its third-quarter 2025 financial results. The company reported a 4% increase in net revenue, reaching approximately $3.1 million compared to the previous quarter's $3.0 million. Despite this modest growth, Mytesi prescription volumes saw a slight rise of 0.9% from the second quarter but a year-over-year decline of 3.6%.

In terms of expenses, Jaguar Health noted significant cost management. Research and Development expenses fell by $0.3 million owing to the completion of a key clinical trial. However, General and Administrative costs increased by $0.3 million, mainly attributed to higher legal expenses. Overall, the net loss for the quarter decreased by $0.4 million to $9.5 million.

The company also highlighted a groundbreaking 37% reduction in parenteral support due to its drug, crofelemer, for infants with MVID.